A Recent Drug Trials shows Lowered High Blood Fats
Published: 11 Mar 2026
Author: Precedence Research
According to the recent study, a leading master switches in the fat releasing system is a protein called Liver X Receptor or LXR that help control various genes that are responsible for making and deleting fats. Now researchers at Johan Auwerx at EPFL and Mani Subramanian at OrsoBio have resolved this issue with an orally administered compound having capability to repress the XLR activity specifically in the liver and gut to lower triglycerides which would not work against body’s natural rhythm and protective cholesterol pathways. The compound is known as TLC-276 and refer as an inverse agonist for the LXR. It further makes the receptor signal work inversely as its main functioning. The study is released in Nature Medicine, which is the first of this kind of tested in humans.
How Did the Study Proceeded?
The researchers began by analyzing huge datasets about human genetics to detect which LXR variant is related to the biomarkers for enhanced triglycerides in the blood. The data showcased a genetics variant within LXR alpha which is highly found in the liver. It was again finalized via a powerful method called Mendelian Randomization that found a causal relationship between gene expression and its results. In this case, it's confirmed that higher LXR alpha expression can trigger triglycerides upwards, and the finding helps select TLC-2716 as an effective compound that can be tested against LXR alpha.
The next steps moved towards a safety approach. Toxicology study performed onto mice and non-human primates along with pharmacokinetics analysis detects that TLC-2716 is largely stays in the gut and liver. It showed limited exposure to other tissues where LXR inhibition can be a risky game. Hence addressing a major issue of developing drugs for metabolic diseases treatment that are highly linked to the excessive number of triglycerides stored in the body.
According to Precedence Research, the Human High Density Lipoprotein (Human HDL) Market size accounted for USD 106.52 billion in 2025 and is predicted to increase from USD 119.84 billion in 2026 to approximately USD 345.90 billion by 2035 expanding at a CAGR of 12.50% from 2026 to 2035 as demand grows for faster, scalable drug production technologies that can assist a safer fat loss without interrupting body’s natural internal clocks.
Next level was the lab findings set at the stage of randomized and placebo-controlled phase-1 study in healthy adults where Participants has received TLC-2716 for 14 days and given a single dose per day and this trial was completely focused on a safety and tolerability and the authors reports that the drug met these endpoints. It was a short trial and still received a notable result. At the highest dosage of TLC- 2716 the triglycerides were reduced up to 38.5% while after meal, the cholesterol dropped by as much as 61%. It was even noticed when participants have started with relatively normal lipid levels and without the use of different lipid-lowering drugs.
A recent report by Precedence Research highlights that Human High-Density Lipoprotein (Human HDL) Market is benefiting from active research and development of cholesterol reducing drugs and its rapid usage among patients with obesity related diseases.